08 de març 2019

Never ending health reforms

Reformas pendientes en la organización de la actividad sanitaria

A new issue of Cuadernos ICE shows the current state of the health system. You'll find an article that explains the main constraints to be overcome with all the details. Above all, in my opinion is the quality of institutions. The remaining articles are highly recommended as well.
We are living on a slippery slope and nobody cares about it, it seems that key decision makers have forgotten to read and accept facts as they are. I strongly suggest a reading of these articles. Something should be done to avoid having to rewrite the same a decade later, as it has happened. Maybe the reforms never end because they still have to start.
Take a chance, play your part. Don't wait too long.

PS. Facts (1) and (2)



You can cry a million tears 

You can wait a million years 

If you think that time will change your ways 

Don't wait too long
When your morning turns to night 

Who'll be loving you by candlelight

If you think that time will change your ways 

Don't wait too long
Maybe I got a lot to learn 

Time can slip away 

Sometimes you got to lose it all 

Before you find your way
Take a chance, play your part 

Make romance, it might brake your heart 

But if you think that time will change your ways 

Don't wait too long
It may rain, it may shine 

Love will age like fine red wine 

But if you think that time will change your ways 

Don't wait too long
Maybe you and I got a lot to learn 

Don't waste another day 

Maybe you got to lose it all 

Before you find your way
Take a chance, play your part 

Make romance, it might break your heart 

But if you think that time will change your ways 

Don't wait too long 

Don't wait 

Hmm... Don't wait

Compositors: Jesse Harris / Larry Klein / Madeline Peyroux


Definitely, this is the message

07 de març 2019

Revisiting the economic foundations of health insurance

Choose to Lose: Health Plan Choices from a Menu with Dominated Option

We know that more choice is not always better. Former posts have emphasized this issue. Loewenstein et al. provide remarkable evidence of what happens with health insurance:
Our findings offer perhaps the strongest evidence to date that insurance reveal as much or more about consumer understanding than about actual health-related risk preferences. In this sense, our setting provides a rare opportunity to conduct a specification check on
the standard insurance demand model absent search frictions.
Our findings challenge the standard practice of inferring risk preferences from insurance choices and raise doubts about the welfare benefits of health reforms that expand consumer choice.
If this is so, many books should be rewritten asap.

PS. G. Loeweinstein will be in Barcelona next week at Barcelona Jocs.


04 de març 2019

Pharma landscape

The Global Use of Medicine in 2019 and Outlook to 2023

The summary of IQVIA report:

  • Global spending on medicines reached $1.2 trillion in 2018 and is set to exceed $1.5 trillion by 2023.
  • Invoice spending in the United States is expected to grow at 4– 7% to $625–655 billion across all channels, but net manufacturer revenue is expected to be 35% below invoice and have growth of 3-6% as price growth slows on both an invoice and net basis.
  • Net drug prices in the United States increased at an estimated 1.5% in 2018 and are expected to rise at 0–3% over the next five years.
  • China reached $137 billion in medicine spending in 2018, but will see growth slow to 3-6% in the next five years as central government reforms to expand insurance access to both rural and urban residents, as well as expansions and modernizations of the hospital system and primary care services have been largely achieved and efforts shift to cost optimization and addressing corruption.
  • Medicine spending in Japan totaled $86 billion in 2018, however spending on medicines is expected to decline from -3 to 0% through 2023, due to the effect of exchange rates and continued uptake of generics and offset by the uptake of new products.
  • The number of new products launched is expected to increase from an average of 46 in the past five years to 54 through 2023, and the average spending in developed markets on new brands is expected to rise slightly to $45.8 billion in the next five years, but represent a smaller share of brand spending



01 de març 2019

Rescuing citizens from the "rule of rescue"

People feel a need to rescue identifiable individuals facing avoidable death or harm. This is a well known fact  explained in 1968 by the Nobel laureate Thomas Schelling from an economic perspective  and by Jonsen  in the bioethics context in 1986.
"A single death is a tragedy; a million deaths is a statistic." This quote reflects exactly what we are talking about. However, the issue is: Do you accept the rescue at any price with public money?
These previous posts of this blog: (1) and (2) explain the details. I'll not insist on what I've already said. I suggest you have a look at them.
Today you can asess these three facts:
1. A country spends 38m € in drugs for 249 patients in 2018. A lifetime treatment.
2. A country has a waiting list of 132.025 patients for surgery, 123.249 patients for diagnostic tests, and 424.715 patients waiting for a visit to the specialist. Total people waiting: 679.989 patients in a country with 7.543.825 inhabitants. 9% of the population is in the waiting list for a health service. However, 25% have voluntary duplicate insurance and could jump the list. Therefore the exact figure is 12% of inhabitants waiting.
3. A country knows that spending 10m € in addition every year can increase cardiac surgery by 600 interventions. This means 600 critical patients less in the waiting list. With 38m €, the number of cardiac interventions would be 2.280.
 Ask yourself what to do about it, what would you prefer to do with 38m€ every year ? Just apply them to 249 patients or to 2.280 (you are not on the waiting list, and we'll assume the same adjusted quality of life years for both cases). Anyway, it's too late to have your answer, the government has already decided for you, and maybe you don't agree with it, as I don't agree. The government prefers the rescue of 249 citizens.
Just to finish, check this final fact:
This country spends 1.192 € per capita of public budget on health. Another country under the same mandatory tax system is able to spend 1.635 €, 40% more !!!
More money allows to avoid such dilemmas for this country. Ask yourself if you want to stay in the former tax system that is damaging your health. Once you have the answer, you'll understand why this country wants to leave this unfair tax system as soon as possible.



23 de febrer 2019

Pharma returns

Measuring the return from pharmaceutical innovation 2018

Key findings for top 12 biopharma companies in the Deloitte study.
  • R&D returns have declined to 1.9 per cent, down from 10.1 per cent in 2010 - the lowest level in nine years
  • Returns have been impacted by the growing cost of bringing a drug to market which now stands at $2,168 million – almost double the $1,188 million recorded in 2010
  • Forecast peak sales have declined from last year to $407 million – less than half the 2010 value of $816 million
The growing cost of new drugs includes buying companies for their research (outsourcing research) instead of "producing" R&D within the company. The report will not tell you this minor observation.
Last February I said :
In drug industry the probability of R&D failure is 90.4%. We all know that in the drug costs we are paying also for failures, but we easily forget the figure.
You'll not find any reference to this minor issue. Is there any profitable industry with such a failure rate?


Caro Emerald

22 de febrer 2019

The bioethics of machine clinical decision making

Artificial intelligence (AI) in healthcare and research
Regulation of predictive analytics in medicine

This is what a brief note from Nuffield Council of Bioethics says about artificial intelligence in healthcare:
The use of AI raises ethical issues, including:
  • the potential for AI to make erroneous decisions; 
  • the question of who is responsible when AI is used to support decision-making; 
  • difficulties in validating the outputs of AI systems; inherent biases in the data used to train AI systems; 
  • ensuring the protection of potentially sensitive data; 
  • securing public trust in the development and use of AI; 
  • effects on people’s sense of dignity and social isolation in care situations; 
  • effects on the roles and skill-requirements of healthcare professionals; 
  • and the potential for AI to be used for malicious purposes.
A key challenge will be ensuring that AI is developed and used in a way that is transparent and compatible with the public interest, whilst stimulating and driving innovation in the sector.
This statement is naive.(From m-w, naive:  marked by unaffected simplicity : INGENUOUS). Up to now, have you seen any transparent algorithm available for imaging, triage or any medical app? For sure not. Therefore, the real key challenge is to stop introducing such algorithms -to ban apps- unless there is a regulatory body that takes into account the quality assurance or effectiveness side (sensitivity and specificity) and the required transparency for citizens.
Until now Nuffield has released only a brief. Let's wait for the report.
If you want a quick answer, check Science this week:
To unlock the potential of advanced analytics while protecting patient safety, regulatory and professional bodies should ensure that advanced algorithms meet accepted standards of clinical benefit, just as they do for clinical therapeutics and predictive biomarkers. External validation and prospective testing of advanced algorithms are clearly needed
 They explain the five standards and give rules and criteria for regulation. It is really welcome.



21 de febrer 2019

Pharm niche busters

The Information Pharms Race and Competitive Dynamics of Precision Medicine: Insights from Game Theory
Economic Dimensions of Personalized and Precision Medicine
Precision medicines inherently fragment treatment populations, generating small-population markets, creating high-priced “niche busters” rather than broadly prescribed “blockbusters”. It is plausible to expect that small markets will attract limited entry in which a small number of interdependent differentiated product oligopolists will compete, each possessing market power.
A chapter in a new book on  Precision Medicine explains the new approaches to a oligopolistic market structure where the size of the market may be determined by biomarkers with a cut-off value suggested by pharmaceutical firms themselves. The dynamics of this market is described according to game theory. Sounds fishy at least.
I already have pending chapters to read of this book. A must read for physicians and economists.



16 de febrer 2019

Defining roles and skills for digital health

The Topol Review
Preparing the healthcare workforce to deliver the digital future.

The NHS asked Dr. Eric Topol about the new health workforce and how digital health will change the current landscape. A must read:
This is an exciting time for the NHS to benefit and apitalise on technological advances. However, we must learn from previous change projects. Successful mplementation will require investment in people as well s technology. To engage and support the healthcare workforce in a rapidly changing and highly technological orkplace, NHS organisations will need to develop a learning environment in which the workforce is given very encouragement to learn continuously. We must better understand the enablers of change and create culture of innovation, prioritising people, developing an agile and empowered workforce, as well as digitally capable leadership, and effective governance processes
to facilitate the introduction of the new technologies, supported by long-term investment.

15 de febrer 2019

Who is worse off?

Health, priority to the worse off, and time

The prioritisation of resource allocation towards the worse off is a well known rule. What does this mean exactly?
 There are many dimensions in which someone can be worse off (e.g., in terms of wellbeing, health, opportunities, resources), and there are many ways to give priority to someone (e.g., by giving extra weight to their claims, lexical priority to their claims, or by earmarking a fixed amount of resources for their claims). Furthermore, there are many different reasons why one might want to give priority to benefits to the worse off: is it because it is good to promote equality for its own sake, good to promote equality for other reasons, because benefits to the worse off matter more, because the worse off typically fall under some sufficiency threshold, or for many of these (and maybe other) reasons
The precise argument is described in a recent article that combines the complete lives approach with the forward looking approach, and says:
 I believe that the focus on complete lives has been beneficial in that it is a step away from a complete focus on current distributions of health. However, I think that the arguments presented in this paper give us reason to adopt a more nuanced approach to how to rank individuals in terms of who is worse off with the purpose of giving priority to certain benefits in light of unequal distributions of health over time. Such an approach accepts that both the complete lives view and the forward looking view that only takes into account current and future health states, matter. This leads to the complicated question of how to combine these views. Some work that addresses how to combine  concerns for simultaneous segment inequality and complete lives inequality has appeared recently, but the question needs further attention.
Therefore, it is still a work in progress.


08 de febrer 2019

The perfect storm of surveillance capitalism


THE DEFINITION
1. A new economic order that claims human experience as free raw material for hidden commercial practices of extraction, prediction, and sales;
2. A parasitic economic logic in which the production of goods and services is subordinated to a new global architecture of behavioral modification;
3. A rogue mutation of capitalism marked by concentrations of wealth, knowledge, and power unprecedented in human history;
4. The foundational framework of a surveillance economy;
5. As significant a threat to human nature in the twenty-first century as industrial capitalism was to the natural world in the nineteenth and twentieth;
6. The origin of a new instrumentarian power that asserts dominance over society and presents startling challenges to market democracy;
7. A movement that aims to impose a new collective order based on total certainty;
8. An expropriation of critical human rights that is best understood as a coup from above: an overthrow of the people’s sovereignty.
Last month in my post on the book: Modern monopolies I wanted to highlight the current trend towards monopolies using platforms as a business model. Now you may add a complementary perspective with the book: The age of surveillance capitalism. While the former emphasizes the business perspective, the later focus on behavioral prediction surplus and how it is generated. It provides a social perspective of the current "surveillance capitalism". In my opinion there is a lot of current economy that already confirms this view, it is not a future expectation.
Our lives are rendered as behavioral data in the first place; ignorance is a condition of this ubiquitous rendition; decision rights vanish before one even knows that there is a decision to make; there is no exit, no voice, and no loyalty, only helplessness, resignation and psychic numbing; encryption is the only positive action left to discuss.
Surveillance capitalists take command of the essential questions that define knowledge, authority, and power in our time: Who knows? Who decides? Who decides who decides? 
As you may imagine, this is a book that once you started it's impossible to stop reading. Highly recommended if you want to understand current hot topics and social trends.
A perfect storm is an event in which a rare combination of circumstances drastically aggravates the event. This is exactly what we have right now in front of us, and as we are inside the wave we are not able to recognise what's going on.

07 de febrer 2019

Medicine as a data science (5)

A guide to deep learning in healthcare

Some months ago, Mckinsey released a guide to AI for executives. It says:
Deep learning is a type of machine learning that can process a wider range of data resources, requires less data preprocessing by humans, and can often produce more accurate results than traditional machine-learning approaches (although it requires a larger amount of data to do so). In deep learning, interconnected layers of software-based calculators known as “neurons” form a neural network. The network can ingest vast amounts of input data and process them through multiple layers that learn increasingly complex features of the data at each layer. The network can then make a determination about the data, learn if its determination is correct, and use what it has learned to make determinations about new data. For example, once it learns what an object looks like, it can recognize the object in a new image.
Now Nature publishes a helpful review article on deep learning in healthcare.
Some of the greatest successes of deep learning have been in the field of computer vision (CV). CV focuses on image and video understanding, and deals with tasks such as object classification, detection, and segmentation—which are useful in determining whether a patient’s radiograph contains malignant tumors
The next step is speech and text. Some advances are already available. Basically, Tensorflow by Google is feeding the beast.

PS. WHO and the classification of digital health interventions 1.0

PS. And the book to read:


04 de febrer 2019

When the regulator doesn't care about the danger within us

A must see Netflix documentary: The bleeding edge. It explains how medical devices are introduced in the market without appropriate control.
CBS news explains some details:


Just because it's new doesn't mean it's better, it may be dangerous and damage you for life. Unfortunately, this is the summary.
And the book to read:


02 de febrer 2019

Medicine as a data science (4)

The practical implementation of artificial intelligence technologies in medicine

One of the critical issues for AI implementation in clinical practice is about privacy. In this article you'll find a clear statement on the impact of EU regulation:
The GDPR will affect AI implementation in healthcare in several ways. First, it requires explicit and informed consent before any collection of personal data. Informed consent has been a long-standing component of medical practice (unlike in social media or onlinebased marketing), but having to obtain informed consent for an  collection of data still represents a higher bar than obtaining consent for specific items, such as procedures or surgical interventions. Second, the new regulation essentially lends power to the person providing the data to track what data is being collected and to be able to request removal of their data. In the healthcare context, this will shift some of the power balance toward the patient and highlights the importance of ongoing work needed to protect patient privacy and to determine appropriate governance regarding data ownership. 
More details inside.

Potential roles of AI-based technologies in healthcare.


 Integration of patient health information at multiple interfaces.







01 de febrer 2019

Medicine as a data science (3)

High-performance medicine: the convergence of human and artificial intelligence

If you want to know the current state of artificial intelligence in medicine, then Eric Topol review in Nature is the article you have to read. A highlighted statement:
There are differences between the prediction metric for a cohort and an individual prediction metric. If a model’s AUC is 0.95, which most would qualify as very accurate,
this reflects how good the model is for predicting an outcome, such as death, for the overall cohort. But most models are essentially classifiers and are not capable of precise prediction at the individual level, so there is still an important dimension of uncertainty.
And this is good summary:
Despite all the promises of AI technology, there are formidable obstacles and pitfalls. The state of AI hype has far exceeded the state of AI science, especially when it pertains to validation and readiness for implementation in patient care. A recent example is IBM Watson Health’s cancer AI algorithm (known as Watson for Oncology). Used by hundreds of hospitals around the world for recommending treatments for patients with cancer, the algorithm was based on a small number of synthetic, nonreal cases with very limited input (real data) of oncologists. Many of the actual output recommendations for treatment were shown to be erroneous, such as suggesting the use of bevacizumab in a patient with severe bleeding, which represents an explicit contraindication and ‘black box’ warning for the drug. This example also highlights the potential for major harm to patients, and thus for medical malpractice, by a flawed algorithm. Instead of a single doctor’s mistake hurting a patient, the potential for a machine algorithm inducing iatrogenic risk is vast. This is all the more reason that systematic debugging, audit, extensive simulation, and validation, along with prospective scrutiny, are required when an AI algorithm is unleashed in clinical practice. It also underscores the need to require more evidence and robust validation to exceed the recent downgrading of FDA regulatory requirements for medical algorithm approval

Therefore, take care when you look at tables like this one:



PredictionnAUCPublication (Reference number)
In-hospital mortality, unplanned readmission, prolonged LOS, final discharge diagnosis216,2210.93* 0.75+0.85#Rajkomar et al.96
All-cause 3–12 month mortality221,2840.93^Avati et al.91
Readmission1,0680.78Shameer et al.106
Sepsis230,9360.67Horng et al.102
Septic shock16,2340.83Henry et al.103
Severe sepsis203,0000.85@Culliton et al.104
Clostridium difficile infection256,7320.82++Oh et al.93
Developing diseases704,587rangeMiotto et al.97
Diagnosis18,5900.96Yang et al.90
Dementia76,3670.91Cleret de Langavant et al.92
Alzheimer’s Disease ( + amyloid imaging)2730.91Mathotaarachchi et al.98
Mortality after cancer chemotherapy26,9460.94Elfiky et al.95
Disease onset for 133 conditions298,000rangeRazavian et al.105
Suicide5,5430.84Walsh et al.86
Delirium18,2230.68Wong et al.100